Clinical Trial

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-06-01; most recent amendment 2025-08-18.
Status change: Recruiting → Active, Not Recruiting 2025-04-02
Status change: Not Yet Recruiting → Recruiting 2022-03-11
Trial Details
NCT Number NCT04910022
Lead Sponsor Nerviano Medical Sciences
Conditions Glioblastoma, Diffuse Glioma
Enrollment 150 participants
Start Date 2021-12-01
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-09-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-19